Doc's note: Back in the day, if a company really wanted to thrive, it needed to start trading on Wall Street. That meant access to a huge revenue stream from investors who couldn't invest in a private company.
But today, as Luke Lango (from our corporate affiliate InvestorPlace) writes, that is changing. And regular investors are missing out on big opportunities...
In January 1976, a scientist and a venture capitalist met at a San Francisco bar to discuss a new idea.
One of the men, Herbert Boyer, had helped develop a method for cutting and recombining DNA. This technique could, in theory, instruct living cells to produce proteins the human body needed but couldn't manufacture on its own.
The other man was 28-year-old Robert Swanson, who believed Boyer's discovery could become the foundation of an entirely new kind of medicine. Instead of synthesizing compounds in a lab, you could engineer cells to produce drugs that had never existed before – which we know today as biotechnology.
Boyer had initially agreed to give Swanson 10 minutes.
Ten minutes became several hours and a few beers. By the end of the conversation, they had agreed to start a company together.
They called it Genentech − short for "genetic engineering technology."
Four years later, the company went public. Back then, biotechnology barely existed as an industry. The company had not yet won approval for a single medicine. Its entire premise − that you could reliably program living organisms to manufacture drugs − had not yet been proved commercially.
Investors rushed in anyway. Genentech offered 1 million shares at $35 each. It closed the day at $71.25 − a 104% gain before the company had sold a single product approved by the U.S. Food and Drug Administration.
Those investors clearly understood that they were early. The entire commercial promise of biotechnology still lay ahead. The stock market was opening a door to an industry in its infancy, and investors could walk through it.
But that was 1980. The AI boom is operating by completely different rules.
Today, I'm going to show you how those rules have changed and why it matters hugely for your money.
The Stock Market Used to Arrive First
Genentech's story wasn't unusual for its era. It was the norm.
Microsoft (MSFT), Amazon (AMZN), and Nvidia (NVDA) all reached the stock market while their biggest growth stories were still largely ahead of them. So investors who bought after the IPO still got in early.
In each case, the opening bell was an invitation to join a journey that had barely begun.
The AI economy works differently.
Many AI companies follow a different path. OpenAI is worth hundreds of billions of dollars without ever having gone public. Anthropic may reach a trillion-dollar valuation before it goes public. Even SpaceX spent decades creating value before Wall Street ever had a chance to participate.
That pattern is not a coincidence. It is a consequence of how the technology industry has changed.
Why Wall Street Isn't Necessary Anymore
Young companies once needed Wall Street. Going public gave them access to capital they couldn't raise any other way − which they used to hire engineers, build infrastructure, and scale operations before they could fund the growth themselves.
Today's most ambitious AI companies don't have that problem...
Deep-pocketed investors funnel hundreds of billions of dollars into AI companies that aren't listed on the stock market. OpenAI raised $122 billion in a single funding round. Anthropic raised billions from Amazon and Alphabet (GOOGL) before its IPO was anywhere in sight. The capital that once required the stock market is now available without it.
The stock market still brings in money, of course. But with it also come quarterly earnings pressure, extensive regulations, activist shareholders, and constant public scrutiny. If a company can fund its growth without accepting those obligations, its founders may decide there's no reason to hurry.
And there's one more reason AI companies are waiting to go public... the lure of acquisition offers.
Tech's largest companies are racing to secure models, data, energy, robotics, security, and specialized talent. When a young business solves an urgent problem, it may receive an acquisition offer long before the stock market becomes necessary.
In that case, while early investors still get paid, and the company still creates incredible value, ordinary folks never get the chance to participate.
This has produced something unusual: two completely separate AI-investment timelines running simultaneously.
The first timeline plays out in public... when Nvidia reports record chip demand, Microsoft announces a new data center, or Alphabet releases a new model. Investors can watch these developments unfold in real time and make decisions accordingly.
The second timeline is almost invisible. It starts when a small team solves a problem no one else has solved. By the time Wall Street hears about it, the earliest investors have already captured much of the upside.
Genentech's public investors got in before biotechnology had proved it could work at scale. They were early enough that decades of value creation still lay ahead of them.
Today, the equivalent moment increasingly happens before the stock market ever gets involved.
That's the shift. And for most investors, it has meant watching the AI boom's biggest fortunes be created in rooms they were never invited into.
Look for These Three Things Before You Invest
For most of recent history, there was no legitimate answer to this problem for ordinary investors.
That is beginning to change − not completely, and not without limits, but in ways that matter.
That's because certain developments in recent years have created pathways that genuinely did not exist before. Individual investors can now evaluate opportunities in ways that would previously have been unavailable to them.
I've spent the past year applying a disciplined framework to these opportunities that I call "PPT." Here's how that breaks down...
People: Are the founders the kind of people who figure things out when everything goes wrong? Do they have the technical depth, relationships, and resilience to build something real?
Product: Does it solve a genuine, urgent, expensive problem, or is it a thin marketing layer built on someone else's technology? Are customers actually paying for it, or just saying they're interested?
Timing: Is the market ready for this right now? Is this company in the direct path of the capital and attention currently flooding the AI economy, or is it a decade too early?
Early-stage companies fail. The goal of PPT isn't to eliminate risk. It's to evaluate that risk with the same discipline successful early investors have always used.
Robert Swanson walked into a bar in 1976 with a theory and walked out with the beginnings of an industry. The investors who invested early were the ones who truly got rich from what he built.
The AI boom is producing the same dynamic, at a scale that dwarfs anything biotechnology has ever created... but it's doing so without the stock market. So you need to make sure you're ready with the right know-how to evaluate these opportunities for yourself.
Sincerely,
Luke Lango
Editor's note: Luke knows where to look for the next wave of breakthrough companies before they hit the mainstream. And his "backdoor" method of investing in them could earn you 51 times more than stocks.
He covered all the details of this strategy in a webinar earlier this week. He explained the hidden opportunity behind the AI boom, how insiders earn outsized gains, and how you can access this same approach. Click here to learn more.